Liu, J., Heddleston, J., Perkins, D.R., Chen, J.J.H., Ghanbarpour, A., Smith, B.W., Miles, R., Aihara, E. and Afshar, S. Scientific Reports 14, no. 1 (2024): 13437.
- Protein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, 92121, USA
- Biotechnology Research, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46221, USA
- Genetic Medicine, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46221, USA
Synthetic peptides were ordered from CPC scientific with > 95% purity. NNJA peptides in the formats of monomer or dendrimer were conjugated by click chemistry to siRNA targeting hypoxanthine–guanine phosphoribosyltransferase (HPRT) gene [..]
Development of a selective, sensitive and robust oxyntomodulin dual monoclonal antibody immunoassay.
Umberger, T.S., Ming, W., Cox, J.M., Konrad, R.J. and Siegel, R.W. Bioanalysis 14, no. 18 (2022): 1229-1239.
- Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN46285, USA
Human K2 EDTA and P800 plasma (500 μl) was spiked with proglucagon 33–61, 35–61 and 36–61 stable-isotope-labeled internal standard peptides (CPC Scientific, custom order) and diluted with I buffer (25 mmol/l Tris-HCl, 25 mmol/l HEPES, 300 mmol/l NaCl, 0.1% (v/v) octyl β-D-glucopyranoside, pH 7.5).
Kirk, N.S., Chen, Q., Wu, Y.G., Asante, A.L., Hu, H., Espinosa, J.F., Martínez-Olid, F., Margetts, M.B., Mohammed, F.A., Kiselyov, V.V. and Barrett, D.G. Nature Communications 13, no. 1 (2022): 5695.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Peptides were synthesized under contract by CPC Scientific, except for the N-terminally acetylated version of IM172N22 and the Glu3Arg, Glu3Ala, Glu4Arg, Glu4Ala, Glu5Ala, Glu5Arg, Trp6Ala, Gln8Ala, Ile9Ala, Glu10Ala, Glu10Arg and Tyr14Ala mutants of IM172N22
Coskun, T., Urva, S., Roell, W.C., Qu, H., Loghin, C., Moyers, J.S., O’Farrell, L.S., Briere, D.A., Sloop, K.W., Thomas, M.K. and Pirro, V. Cell Metabolism 34, no. 9 (2022): 1234-1247.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Homologous and heterologous competition experiments were performed with non-radioactive peptide analogues[127I]-Tyr1-GIP(1-42) and [127]-Tyr10-GIP(1-42) to ensure quantification of the high-affinity binding site of the GIPR. Peptide analogues were generated using synthetic [127I]-Tyr amino acid building blocks (CPC Scientific).
Liao, Z., Zhang, C., Ding, L., Moyers, J.S., Tang, J.X. and Beals, J.M. The FEBS Journal 289, no. 9 (2022): 2657-2671.
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Synthetic peptides of hIR-B were purchased from CPC Scientific..
Willard, F.S., Wainscott, D.B., Showalter, A.D., Stutsman, C., Ma, W., Cardona, G.R., Zink, R.W., Corkins, C.M., Chen, Q., Yumibe, N. and Agejas, J. Journal of Medicinal Chemistry 64, no. 6 (2021): 3439-3448
- Discovery Chemistry Research and Technologies, Diabetes and Complications, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN 46285 and S2.
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
Synthetic peptides were synthesized at Eli Lilly, Bachem (Torrance, CA), or CPC Scientific (Sunnyvale, CA) to >95% purity.
Bueno, A.B., Sun, B., Willard, F.S., Feng, D., Ho, J.D., Wainscott, D.B., Showalter, A.D., Vieth, M., Chen, Q., Stutsman, C. and Chau, B. Nature Chemical Biology 16, no. 10 (2020): 1105-1110.
- Lilly, S.A., Alcobendas, Spain.
- ConfometRx, Santa Clara, CA, USA.
- Departments of Quantitative Biology, Discovery Chemistry Research and Technologies, and Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
- Lilly Biotechnology Center San Diego, San Diego, CA, USA.
Peptides were synthesized and purified to >95% purity at Eli Lilly and Company or purchased from CPC Scientific or Tocris. GLP-1(9-36)NH2, GLP-1(7-36)NH2, OXM(1-37)OH and GIP(1-42)NH2 were used for pharmacology experiments, and GLP-1(7-37)OH was used for cryo-EM studies.
Pandya, P., Sayers, R.O., Ting, J.P., Morshedian, S., Torres, C., Cudal, J.S., Zhang, K., Fitchett, J.R., Zhang, Q., Zhang, F.F. and Wang, J. PLoS One 15, no. 6 (2020): e0233961.
- Departments of Protein Engineering, Eli Lilly Biotechnology Center, Discovery Chemistry Research and Technologies, San Diego, California, United States of America
- Departments of Structural Biology, Quantitative Biology, and Recombinant Protein Generation, Discovery Chemistry Research and Technologies, and, Eli Lilly and Company, Indianapolis, Indiana, United States of America
- Centro de Investigacio´n Lilly, Alcobendas, Spain
Peptide synthesis was outsourced to CPC Scientific.
Froning, K., Maguire, J., Sereno, A., Huang, F., Chang, S., Weichert, K., Frommelt, A.J., Dong, J., Wu, X., Austin, H. and Conner, E.M. Nature Communications 11, no. 1 (2020): 2330.
- Eli Lilly Biotechnology Center, 10300 Campus Point Drive, San Diego, CA 92121, USA
SLLMWITQC (NY-ESO-1) peptide (synthesized by CPC Scientific), 100 μL total volume, for 3 h.
Cox, J.M., Berna, M.J., Jin, Z., Cox, A.L., Sloop, K.W., Gutierrez, J.A. and Ackermann, B.L. Bioanalysis 8, no. 15 (2016): 1579-1595.
- 1 Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
"The OXM peptides 1–37, 3–37 and 4–37 as well as their corresponding stable isotope-labeled internal standards (each containing one [ 13 C 9 , 15 N]-labeled phenylalanine and two [ 13 C 6 , 15 N]-labeled leucine residues) were synthesized by CPC Scientific, Inc."
